Summary: The legal case at hand involves Jaclyn Bjorklund, the plaintiff, who has filed a lawsuit against pharmaceutical giants Novo Nordisk and Eli Lilly. The basis of the lawsuit is personal injury and product liability claims. Bjorklund asserts that she has experienced severe and irreversible injuries, such as excessive vomiting, gastroparesis, and gastroenteritis, as a result of using two injectable prescription medications, Ozempic and Mounjaro. These medications are typically prescribed to manage blood sugar levels in adults diagnosed with type 2 diabetes. Bjorklund contends that the defendants did not provide sufficient warning about the potential severity of these gastrointestinal side effects. The lawsuit further accuses the pharmaceutical companies of deceptive marketing and promotion of these drugs. Novo Nordisk is specifically accused of aggressively promoting Ozempic through various platforms, including television commercials and social media, without adequately disclosing the potential for severe gastrointestinal risks. Eli Lilly faces similar accusations related to their promotion of Mounjaro. Bjorklund alleges that the defendants were involved in every stage of these products' lifecycle, from design and research to manufacturing, testing, advertising, promotion, marketing, sales, and distribution, without adequately disclosing the potential risks. The lawsuit references numerous medical literature and case reports that establish a link between the use of these drugs and the onset of gastroparesis symptoms. It also highlights a warning issued by the American Society of Anesthesiologists about the use of Ozempic prior to elective surgery. The lawsuit has been filed in the United States District Court for the Western District of Louisiana. Bjorklund, represented by the law firm Morgan & Morgan, has requested a jury trial. She is seeking compensation for physical pain, mental distress, reduced quality of life, and the necessity for ongoing medical treatment resulting from the use of these drugs.